Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate-to-Severe Plaque Psoriasis Who Are Naive to Systemic Treatment With an Extension Period
Brief Summary: The main purpose of this study is to evaluate the efficacy of ixekizumab compared to fumaric acid esters (FAE) and methotrexate (MTX) in participants with moderate-to-severe plaque psoriasis who are naive to systemic treatment.


Options:
A: Arm Label: BCD-085 Q2W; Type: EXPERIMENTAL; Interventions: Drug: BCD-085 Q2W | Arm Label: BCD-085 Q4W; Type: EXPERIMENTAL; Interventions: Drug: BCD-085 Q4W | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCD-085 Q2W; Assigned to Arm(s): BCD-085 Q2W | Intervention Type: DRUG; Name: BCD-085 Q4W; Assigned to Arm(s): BCD-085 Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bimekizumab dosing regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 3; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 4; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 5; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab dosing regimen 1, Bimekizumab dosing regimen 2, Bimekizumab dosing regimen 3, Bimekizumab dosing regimen 4, Bimekizumab dosing regimen 5 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab dosing regimen 1, Bimekizumab dosing regimen 2, Bimekizumab dosing regimen 3, Bimekizumab dosing regimen 4, Placebo
C: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2

Answer: C